Profil
Jan Beck is currently the Director at Life Science Washington and a Member at the Association of Washington Business.
He is also the Chief Operating Officer at Mozart Therapeutics, Inc. starting from 2022.
Previously, he worked as the Head-Research & Development Operations at Lyell Immunopharma, Inc.
Postes actifs de Jan Beck
| Sociétés | Poste | Début |
|---|---|---|
Mozart Therapeutics, Inc.
 Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | Directeur des opérations | 21/03/2022 |
| Life Science Washington | Directeur/Membre du Conseil | - |
| Association of Washington Business | Corporate Officer/Principal | - |
Anciens postes connus de Jan Beck
| Sociétés | Poste | Fin |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning. | Health Technology |
| Life Science Washington | |
| Association of Washington Business |
